Suppr超能文献

脂代谢改变作为 LPS 诱导 BBB 破坏的潜在机制。

Alteration of sphingolipid metabolism as a putative mechanism underlying LPS-induced BBB disruption.

机构信息

Pharmazentrum Frankfurt, Institute for General Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.

Department of Neurology, University Hospital Frankfurt and Goethe University, Frankfurt, Germany.

出版信息

J Neurochem. 2018 Jan;144(2):172-185. doi: 10.1111/jnc.14236. Epub 2017 Dec 28.

Abstract

Septic encephalopathy with confusion and agitation occurs early during sepsis and contributes to the severity of the disease. A decrease in the sphingosine-1-phosphate (S1P) blood levels has been shown in patients and in animal models of sepsis. The lipid mediator S1P is known to be involved in endothelial barrier function in a context-dependent manner. We utilized lipopolysaccharide (LPS)-injected mice as a model for septic encephalopathy and first performed tracer permeability assays to assess the blood-brain barrier (BBB) breakdown in vivo. At time points corresponding to the BBB breakdown post LPS injection, we aimed to characterize the regulation of the sphingolipid signaling pathway at the BBB during sepsis. We measured sphingolipid concentrations in blood, in mouse brain microvessels (MBMVs), and brain tissue. We also analyzed the expression of S1P receptors, transporters, and metabolizing enzymes in MBMVs and brain tissue. Primary mouse brain microvascular endothelial cells (MBMECs) were isolated to evaluate the effects of LPS on transendothelial electrical resistance (TEER) as a measure of permeability in vitro. We observed a relevant decrease in S1P levels after LPS injection in all three compartments (blood, MBMVs, brain tissue) that was accompanied by an increased expression of the S1P receptor type 1 and of sphingosine kinase 1 on one hand and of the S1P degrading enzymes lipid phosphate phosphatase 1 (LPP1) and S1P phosphatase 1 on the other hand, as well as a down-regulation of sphingosine kinase 2. Application of LPS to a monolayer of primary MBMECs did not alter TEER, but serum from LPS-treated mice lead to a breakdown of the barrier compared to serum from vehicle-treated mice. We observed profound alterations of the sphingolipid metabolism at the BBB after LPS injection that point toward a therapeutic potential of drugs interfering with this pathway as novel approach for the detrimental overwhelming immune response in sepsis. Read the Editorial Highlight for this article on page 115. Cover Image for this Issue: doi. 10.1111/jnc.14161.

摘要

脓毒症性脑病伴意识混乱和激越发生在脓毒症早期,导致疾病的严重程度增加。已在脓毒症患者和动物模型中显示出鞘氨醇-1-磷酸 (S1P) 血液水平降低。脂质介质 S1P 已知以依赖于上下文的方式参与内皮屏障功能。我们利用脂多糖 (LPS) 注射小鼠作为脓毒症性脑病模型,首先进行示踪剂通透性测定以评估体内血脑屏障 (BBB) 的破坏。在 LPS 注射后对应于 BBB 破坏的时间点,我们旨在描述脓毒症期间 BBB 上鞘脂信号通路的调节。我们测量了血液、小鼠脑微血管 (MBMVs) 和脑组织中的鞘脂浓度。我们还分析了 MBMVs 和脑组织中 S1P 受体、转运体和代谢酶的表达。分离原代小鼠脑微血管内皮细胞 (MBMECs) 以评估 LPS 对体外跨内皮电阻 (TEER) 的影响,TEER 作为通透性的衡量标准。我们观察到 LPS 注射后所有三个隔室(血液、MBMVs、脑组织)中的 S1P 水平显著降低,同时 S1P 受体 1 和鞘氨醇激酶 1 的表达增加,另一方面 S1P 降解酶磷酸酶 1 (LPP1) 和 S1P 磷酸酶 1 的表达增加,以及鞘氨醇激酶 2 的下调。将 LPS 应用于单层原代 MBMECs 不会改变 TEER,但与来自载体处理小鼠的血清相比,来自 LPS 处理小鼠的血清导致屏障破坏。我们观察到 LPS 注射后 BBB 上鞘脂代谢的深刻改变,这表明干扰该途径的药物具有作为脓毒症中有害过度免疫反应的新治疗方法的潜力。阅读本期文章 115 页的社论要点。本期的封面图片:doi.10.1111/jnc.14161。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验